Meticulous Research®—a leading global market research company published a research report titled “Diagnostic Specialty Antibodies Market by Type (Primary, Secondary), Clonality (Monoclonal, Polyclonal), Technique (WB, Rapid Test, IHC, IP), Conjugate, and Application (Dengue, Malaria, Hepatitis, HIV, E. coli , Tuberculosis, Pneumonia, Cancer)- Forecast to 2029”. According to this latest publication from Meticulous Research®, the global diagnostic specialty antibodies market is expected to grow at a CAGR of 4.6% to reach $39.99 billion by 2029.
The high burden of infectious and chronic diseases worldwide, the availability of funding for research activities, the significant demand for pregnancy test kits due to rising incidences of pregnancies, and regulatory approval of test kits are the key factors driving the demand for diagnostic specialty antibodies. The initiatives taken by the public and private organizations to increase diagnostic testing and the increasing incidences of diseases in emerging countries are expected to offer significant opportunities for the growth of this market.
Diagnostic Specialty Antibodies Market: Future Outlook
The global diagnostic specialty antibodies market is segmented based on Type (Primary Antibodies, Secondary Antibodies), Clonality (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies), Technique (Western Blot [WB], Lateral Flow Assay, Enzyme-Linked Immunosorbent Assay [ELISA], Immunohistochemistry [IHC], Immunoprecipitation [IP], Immunocytochemistry [ICC], Other Techniques), Conjugate (Conjugated, Unconjugated), Application (Infectious Diseases [Parasitic Infections: Dengue, Malaria, and Other Parasitic Infections], [Blood Borne Infections: Hepatitis, HIV, and Other Blood Borne Infections], [Gastrointestinal Infections: Salmonellosis, E. Coli Infections, and Other Gastrointestinal Infections], [Respiratory Infections: COVID-19, Tuberculosis, Pneumonia, Influenza, and Other Respiratory Infections], Oncology, Pregnancy Detection/Fertility Testing, and Other Applications), and Geography The study also evaluates industry competitors and analyzes their market share at the global and regional levels.
Based on type, the market is segmented into primary antibodies and secondary antibodies. The primary antibodies segment is estimated to account for the larger share of the market in 2022. The capability of primary antibodies to easily bind to the target antigen is the key factor driving the demand for primary antibodies in the market. In addition, the mandatory requirement of primary antibodies in every assay and the regulatory approvals for primary antibody-based test kits have further promoted the growth of this segment.
Based on clonality, the market is segmented into monoclonal, polyclonal, and recombinant. The recombinant antibody segment is expected to witness the fastest CAGR during the forecast period. Recombinant antibodies can be produced in a shorter duration than other clonal antibodies. These antibodies are more cost-effective and offer a better affinity to bind to the target antigen. Moreover, recombinant antibodies eliminate the problems associated with hybridomas, which further contributes to its demand in the market.
Based on technique, the market is segmented into western blot, ELISA, lateral flow assay, immunohistochemistry, immunoprecipitation, immunocytochemistry, and others. The ELISA segment is estimated to account for the largest share in 2022. ELISA is relatively simple, as compared to western blot and other techniques. Moreover, this test also has high efficiency, specificity, and sensitivity and is relatively cost-effective compared to IHC, western blot, and other assays.
Based on conjugate, the market is segmented into conjugated antibodies and unconjugated antibodies. The unconjugated antibodies segment is estimated to account for the largest share in the market in 2022. The flexibility and specificity offered by unconjugated antibodies in assays is the key factor contributing to the growth of this segment. The launch of unconjugated antibodies for disease diagnosis in the market further contributes to the growth of this segment.
Based on application, the market is segmented into infectious diseases, oncology, blood group typing, pregnancy detection/fertility testing, and others. The infectious diseases segment is estimated to account for the largest share of the market in 2022. The high prevalence of infectious diseases, such as dengue, HIV, influenza, tuberculosis, sepsis, and the initiatives by public and private organizations for early disease testing are the factors driving the market growth of this segment. The growing trend of self-testing kits for testing infectious diseases has further promoted the growth of this segment.
This research report analyzes major geographies and provides a comprehensive analysis for North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), Latin America, and the Middle East & Africa.
North America is estimated to command the largest share of the diagnostic specialty antibodies market in 2022, followed by Europe and Asia-Pacific. The U.S. is estimated to be the largest shareholding market in North America in 2022. The research funding for diseases, such as cancer and AIDS by the National Cancer Institute (NCI), emergency use authorization (EUA) by the U.S. FDA for test kits containing antibodies, and the rising incidences of diseases, such as cancer and COVID-19, are some factors boosting the market growth in the U.S. However, Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.
The key players operating in the global diagnostic specialty antibodies market are Abcam plc (U.K.), F. Hoffman La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Rockland Immunochemicals, Inc. (U.S.), Santa Cruz Biotechnology (U.S.), Novus Biologicals, LLC (U.S.), and Thermo Fisher Scientific Inc. (U.S.).
Download Sample Copy Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5241
Key questions answered in the report-
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research